Analysis of the effectiveness of the combination of bevacizumab and irinotecan for the treatment of glial tumors

Authors

DOI:

https://doi.org/10.33448/rsd-v11i1.25135

Keywords:

Bevacizumab; Irinotecan; Glial tumors; Efficacy.

Abstract

Glial tumors, or gliomas, are the most common type of brain tumor and have a high incidence, most of which are diffuse and prone to extensive infiltration into the brain parenchyma, causing tumor recurrence. High-grade gliomas, such as glioblastomas, are highly angiogenic and have high levels of proangiogenic factors, such as vascular endothelial growth factor (VEGF), essential for tumor neovascularization. The target to inhibit VEGF is bevacizumab, a humanized monoclonal antibody, with association with irinotecan, a topoisomerase I inhibitor. Thus, the objective of the following review is to analyze the effectiveness of the combination of bevacizumab and irinotecan for the treatment of glial tumors . This is a systematic literature review that used the PubMed, SciELO and Google Scholar platforms as a database for researching scientific articles, with a time frame between 2016 and 2021, in English. According to the search engine, 3 results were found after the exclusion criteria in PubMed and Google Scholar databases. Therefore, it was found that the combined chemotherapy of bevacizumab and irinotecan is effective in the treatment of glial tumors, moreover, the combination of both drugs has a higher overall survival rate than the isolated therapy of the antiangiogenic bevacizumab.

References

Ameratunga, M., Pavlakis, N., Wheeler, H., Grant, R., Simes, J., & Khasraw, M. (2018). Anti‐angiogenic therapy for high‐grade glioma. Cochrane Database of Systematic Reviews, (11).

Bergman, D., Modh, A., Schultz, L., Snyder, J., Mikkelsen, T., Shah, M., ... & Walbert, T. (2020). Randomized prospective trial of fractionated stereotactic radiosurgery with chemotherapy versus chemotherapy alone for bevacizumab-resistant high-grade glioma. Journal of neuro-oncology, 148, 353-361.

Davis M. E. (2018). Epidemiology and Overview of Gliomas. Seminars in oncology nursing, 34(5), 420–429. https://doi.org/10.1016/j.soncn.2018.10.001

de Man, F. M., Goey, A., van Schaik, R., Mathijssen, R., & Bins, S. (2018). Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. Clinical pharmacokinetics, 57(10), 1229–1254. https://doi.org/10.1007/s40262-018-0644-7

Dong, J., Meng, X., Li, S., Chen, Q., Shi, L., Jiang, C., & Cai, J. (2019). Risk of adverse vascular events in patients with malignant glioma treated with bevacizumab plus irinotecan: A systematic review and meta-analysis. World neurosurgery, 130, e236-e243.

Figueiras, F. N., Duarte, M. L., & Santos, L. R. dos. (2020). Cerebellar pilocytic astrocytoma: literature review and case report of a young patient with anatomopathological correlation. Research, Society and Development, 9(7), e405974115. https://doi.org/10.33448/rsd-v9i7.4115

Li, Y., Ali, S., Clarke, J., & Cha, S. (2017). Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications. Brain tumor research and treatment, 5(1), 1–9. https://doi.org/10.14791/btrt.2017.5.1.1

Lim, M., Xia, Y., Bettegowda, C., & Weller, M. (2018). Current state of immunotherapy for glioblastoma. Nature reviews. Clinical oncology, 15(7), 422–442. https://doi.org/10.1038/s41571-018-0003-5

McBain, C., Lawrie, T. A., Rogozińska, E., Kernohan, A., Robinson, T., & Jefferies, S. (2021). Treatment options for progression or recurrence of glioblastoma: a network meta-analysis. The Cochrane database of systematic reviews, 5(1), CD013579. https://doi.org/10.1002/14651858.CD013579.pub2

Nayak, L., & Reardon, D. A. (2017). High-grade Gliomas. Continuum (Minneapolis, Minn.), 23(6, Neuro-oncology), 1548–1563. https://doi.org/10.1212/CON.0000000000000554

Norden, A. D., & Wen, P. Y. (2006). Glioma therapy in adults. The neurologist, 12(6), 279–292. https://doi.org/10.1097/01.nrl.0000250928.26044.47

Omuro, A., & DeAngelis, L. M. (2013). Glioblastoma and other malignant gliomas: a clinical review. JAMA, 310(17), 1842–1850. https://doi.org/10.1001/jama.2013.280319

Ostrom, Q. T., Bauchet, L., Davis, F. G., Deltour, I., Fisher, J. L., Langer, C. E., Pekmezci, M., Schwartzbaum, J. A., Turner, M. C., Walsh, K. M., Wrensch, M. R., & Barnholtz-Sloan, J. S. (2014). The epidemiology of glioma in adults: a "state of the science" review. Neuro-oncology, 16(7), 896–913. https://doi.org/10.1093/neuonc/nou087

Ostrom, Q. T., Gittleman, H., Stetson, L., Virk, S. M., & Barnholtz-Sloan, J. S. (2015). Epidemiology of gliomas. Cancer treatment and research, 163, 1–14. https://doi.org/10.1007/978-3-319-12048-5_1

Perry, A., & Wesseling, P. (2016). Histologic classification of gliomas. Handbook of clinical neurology, 134, 71–95. https://doi.org/10.1016/B978-0-12-802997-8.00005-0

Sandes , V. dos A. ., Dantas, R. L. ., Porto, R. L. S. ., Reis , F. F. P. ., Sousa , D. S. de ., Lima, S. O. ., Marcena, S. L. S. ., & Reis, F. P. (2020). The occurrence of tumors of the central nervous system in the state of Sergipe from 2008 to 2017. Research, Society and Development, 9(11), e3439119673. https://doi.org/10.33448/rsd-v9i11.9673

Seystahl, K., Wick, W., & Weller, M. (2016). Therapeutic options in recurrent glioblastoma--An update. Critical reviews in oncology/hematology, 99, 389–408. https://doi.org/10.1016/j.critrevonc.2016.01.018

Stylli, S. S., Luwor, R. B., Ware, T. M., Tan, F., & Kaye, A. H. (2015). Mouse models of glioma. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 22(4), 619–626. https://doi.org/10.1016/j.jocn.2014.10.013

Wang, T., & Mehta, M. P. (2019). Low-Grade Glioma Radiotherapy Treatment and Trials. Neurosurgery clinics of North America, 30(1), 111–118. https://doi.org/10.1016/j.nec.2018.08.008

Wesseling, P., & Capper, D. (2018). WHO 2016 Classification of gliomas. Neuropathology and applied neurobiology, 44(2), 139–150. https://doi.org/10.1111/nan.12432

Xiong, L., Wang, F., & Qi Xie, X. (2019). Advanced treatment in high-grade gliomas. Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 24(2), 424–430.

Xu, S., Tang, L., Li, X., Fan, F., & Liu, Z. (2020). Immunotherapy for glioma: Current management and future application. Cancer letters, 476, 1–12. https://doi.org/10.1016/j.canlet.2020.02.002

Downloads

Published

09/01/2022

How to Cite

FONSECA, G. S. G. B. .; LEITE, M. J. F. L. .; COSTA, A. C. N. .; ANDRADE, P. P. .; FREIRE, V. M. L. M. .; MARINHO, L. C. O. .; LIMA, P. de L. .; PACHECO, L. O. P. L. .; BONFIM, L. L. .; AZEVEDO, P. G. de .; BRITTO, F. A. L. C. de .; REIS, L. L. T. .; VIEIRA, I. C. .; MACEDO, G. de S. .; MACEDO, G. M. L. B. .; MESQUITA NETO, A. R. .; BRITO, A. do R. .; PENHA, E. C. da S. .; GUIMARÃES, J. V. A. .; PEREIRA, R. E. L. .; MURAD, L. M. de A. .; OLIVEIRA, R. M. S. .; PRAZERES, J. S. .; COSTA, D. B. .; SILVA, R. L.; SANTOS, A. C. .; GARCIA, A. C. R. . Analysis of the effectiveness of the combination of bevacizumab and irinotecan for the treatment of glial tumors. Research, Society and Development, [S. l.], v. 11, n. 1, p. e37911125135, 2022. DOI: 10.33448/rsd-v11i1.25135. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/25135. Acesso em: 22 nov. 2024.

Issue

Vol. 11 No. 1

Section

Health Sciences

License

Copyright (c) 2022 Gustavo Soares Gomes Barros Fonseca; Maria Julia Fonseca Lima Leite; Ana Clara Nóbrega Costa; Pietra Possapp Andrade; Vivianne Maria Laranjeiras Monte Freire; Luana Caroline Oliveira Marinho; Pedro de Lacerda Lima; Luyla Oliveira Paes Landim Pacheco; Lais Lima Bonfim; Paula Golino de Azevedo; Filipe Augusto Lopes Cajubá de Britto; Lara Letícia Teixeira Reis; Izadora Carneiro Vieira; Gabriel de Sousa Macedo; Gabriel Moreira Lima Bomfim Macedo; Agostinho Rodrigues Mesquita Neto; Alessandra do Rosário Brito; Elana Cristina da Silva Penha; João Victor Araújo Guimarães; Raphael Erick Lima Pereira; Letícia Muniz de Abreu Murad; Rillary Maxine Sales Oliveira; Julianne Souza Prazeres; Déborah Braga Costa; Rebecca Lima Silva; Amanda Cordeiro Santos; Ana Clara Rocha Garcia

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.